2020
638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis
Abdel-Wahab N, Diab A, Katayama H, Kim S, Hanash S, Suarez-Almazor M. 638 Plasma proteome analysis in patients with immune checkpoint inhibitors related arthritis and pneumonitis. Journal For ImmunoTherapy Of Cancer 2020, 8: a674-a674. DOI: 10.1136/jitc-2020-sitc2020.0638.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsRenal cell carcinomaNon-small cell lung carcinomaPlasma proteomic analysisStatistically significant differenceCheckpoint inhibitorsCell carcinomaAdverse eventsBiomarkers of immune-related adverse eventsDevelopment of immune-related adverse eventsPatients treated with immune checkpoint inhibitorsAnti-programmed cell death 1Immune checkpoint inhibitor initiationImmune checkpoint inhibitor treatmentResponse to ICI therapyNon-small cell lung cancerBlood drawThe University of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterAnti-PD1 treatmentAnti-tumor immunityMD Anderson Cancer CenterCell death 1Inflammation of lung tissue
2019
Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare
Kim S, Bittar M, Kim H, Neelapu S, Zurita A, Nurieva R, Suarez-Almazor M. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. Journal For ImmunoTherapy Of Cancer 2019, 7: 126. PMID: 31088575, PMCID: PMC6518723, DOI: 10.1186/s40425-019-0597-x.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsNivolumab infusionAdverse eventsIL-17 producing CD4Immune checkpoint inhibitor therapyImmune checkpoint inhibitor treatmentImmune-related adverse eventsPatients treated with nivolumabCD4+ T cellsAmount of IL-17Characterized immune cellsCheckpoint inhibitor treatmentPD-1 inhibitorsCheckpoint inhibitor therapyCrystal arthritisSynovial fluidRenal cell carcinomaAutoimmune inflammatory arthritisT helper 17Neutrophil-driven inflammationProphylactic colchicinePD-1Inhibitor therapyConclusionsThis case